Levetiracetam, Keppra
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Memory Loss Associated With Corticosteroid Use
Conditions
Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use
Trial Timeline
Feb 1, 2005 → Nov 1, 2005
NCT ID
NCT00223223About Levetiracetam, Keppra
Levetiracetam, Keppra is a approved stage product being developed by UCB for Memory Loss Associated With Corticosteroid Use. The current trial status is completed. This product is registered under clinical trial identifier NCT00223223. Target conditions include Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00223223 | Approved | Completed |
Competing Products
8 competing products in Memory Loss Associated With Corticosteroid Use
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Donepezil Hydrochloride + Placebo | Eisai | Approved | 85 |
| Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine | AstraZeneca | Phase 1 | 33 |
| Aricept + IFN-alpha2A | Pfizer | Phase 2 | 51 |
| Tolterodine ER + Oxybutynin ER | Pfizer | Approved | 84 |
| Piracetam | UCB | Pre-clinical | 20 |
| EGb 761® (Tanakan®) | Ipsen | Approved | 82 |
| LX6171 High Dose + LX6171 Low Dose + Placebo | Lexicon Pharmaceuticals | Phase 2 | 47 |
| Fruitflow-II + resVida | Brain Biotech | Pre-clinical | 15 |